ArticleCancer cell2016
Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
10.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 101 citations in OpenAlex.
- Augment proteasome inhibitor efficacy activates CD8Cell reports. Medicine · 2025Article
- Metabolic reprogramming induced by PSMA4 overexpression facilitates bortezomib resistance in multiple myeloma.Annals of hematology · 2025Article
- Article
- Functional Analysis of Membrane-Associated Scaffolding Tight Junction (TJ) Proteins in Tumorigenic Characteristics of B16-F10 Mouse Melanoma Cells.International journal of molecular sciences · 2024Article
- Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells.Frontiers in pharmacology · 2024Review
- TJP1 promotes vascular mimicry in bladder cancer by facilitating VEGFA expression and transcriptional activity through TWIST1.Translational oncology · 2023Article
- Tight Junction Protein 1 Suppresses Kidney Renal Clear Cell Carcinoma Cells Proliferation by Inducing Autophagy.International journal of medical sciences · 2023Article
- CD31 promotes diffuse large B-cell lymphoma metastasis by upregulating OPN through the AKT pathway and inhibiting CD8+ T cells through the mTOR pathway.American journal of translational research · 2023Article
- Current perspectives on interethnic variability in multiple myeloma: Single cell technology, population pharmacogenetics and molecular signal transduction.Translational oncology · 2022Article
- Direct and indirect effects of IFN-α2b in malignancy treatment: not only an archer but also an arrow.Biomarker research · 2022Review
- Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities.Haematologica · 2022Article
- Pathogenic signaling in multiple myeloma.Seminars in oncology · 2022Article
- Review
- TJP1 Contributes to Tumor Progression through Supporting Cell-Cell Aggregation and Communicating with Tumor Microenvironment in Leiomyosarcoma.Molecules and cells · 2021Article
- The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variability.Genome medicine · 2021Article
- Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression.Haematologica · 2021Article
- Deubiquitinating enzyme inhibitor alleviates cyclin A1-mediated proteasome inhibitor tolerance in mixed-lineage leukemia.Cancer science · 2021Article
- Article
- Article
- HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma.International journal of molecular sciences · 2021Article
Corrections and comments
- Commented on by
Authors and funding
33 authors at 11 institutions in 4 countries.
Xing-Ding ZhangDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Cyrus Tang Hematology Center, Soochow University, Suzhou, Jiangsu 215123, China; Xi'an Jiaotong University Suzhou Academy, Suzhou, Jiangsu 215123, China.
Veerabhadran BaladandayuthapaniDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Heather LinDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
George MulliganMillennium: The Takeda Oncology Company, Cambridge, MA 02139, USA.
Bin LiMillennium: The Takeda Oncology Company, Cambridge, MA 02139, USA.
Dixie-Lee W EsseltineMillennium: The Takeda Oncology Company, Cambridge, MA 02139, USA.
Lin QiXi'an Jiaotong University Suzhou Academy, Suzhou, Jiangsu 215123, China.
Jianliang XuInstitute of Molecular and Cell Biology, Singapore 138673, Republic of Singapore.
Walter HunzikerInstitute of Molecular and Cell Biology, Singapore 138673, Republic of Singapore.
Bart BarlogieMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Saad Z UsmaniMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA; Department of Hematologic Oncology, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC 28204, USA.
Qing ZhangMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA; Department of Hematologic Oncology, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC 28204, USA.
John CrowleyCancer Research and Biostatistics, Seattle, WA 98101, USA.
Antje HoeringCancer Research and Biostatistics, Seattle, WA 98101, USA.
Jatin J ShahDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Donna M WeberDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Elisabet E ManasanchDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Sheeba K ThomasDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Bing-Zong LiDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hui-Han WangDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jiexin ZhangDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Isere KuiatseDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jin-Le TangCyrus Tang Hematology Center, Soochow University, Suzhou, Jiangsu 215123, China.
Hua WangDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jin HeDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jing YangDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Enrico MilanDivision of Genetics and Cell Biology, San Raffaele Scientific Institute, Università Vita-Salute San Raffaele, Milan 20132, Italy.
Simone CenciDivision of Genetics and Cell Biology, San Raffaele Scientific Institute, Università Vita-Salute San Raffaele, Milan 20132, Italy.
Wen-Cai MaDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Zhi-Qiang WangDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Richard Eric DavisDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Lin YangCyrus Tang Hematology Center, Soochow University, Suzhou, Jiangsu 215123, China; Xi'an Jiaotong University Suzhou Academy, Suzhou, Jiangsu 215123, China. Electronic address: yanglin@suda.edu.cn.
Robert Z OrlowskiDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: rorlowsk@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USCancer Research And Biostatistics · USInstitute of Molecular and Cell Biology · SGMillennium Engineering and Integration (United States) · USUniversity of Arkansas for Medical Sciences · USVita-Salute San Raffaele University · ITXi'an Jiaotong University · CNLevine Cancer Institute · USSoochow University · CNTakeda (United States) · USXi’an Jiaotong-Liverpool University · CN
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MSWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1MSWOG - Foreign Accrual under UMiU10CA032102 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BLANKE, CHARLES D. · 1985 to 2013
$141.3MTumor Cell-Microenvironment Interactions in the Molecular Pathogenesis of MultiplP01CA055819 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI BELLAMY, WILLIAM T · 1993 to 2013
$49.7MP4 -TARGETING MULTIPLE MYELOMA BY COMBINING CDK INHIBITORS AND BCL-2 ANTAGONISTSP50CA142509 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KWAK, LARRY W · 2010 to 2014
$11.1MProteasome Assembly Chaperones in Sensitivity and Resistance to Proteasome InhibitorsR01CA194264 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ORLOWSKI, ROBERT ZYGMUNT · 2016 to 2020
$1.8MRole of TJP1 in Sensitivity and Resistance to Proteasome Inhibitors in MyelomaR01CA184464 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ORLOWSKI, ROBERT ZYGMUNT · 2015 to 2019
$1.8MNCI NIH HHS P01 CA055819NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA142509NCI NIH HHS R01 CA184464NCI NIH HHS R01 CA194264NCI NIH HHS U10 CA032102NCI NIH HHS U10 CA180888
Abstract
Proteasome inhibitors have revolutionized outcomes in multiple myeloma, but they are used empirically, and primary and secondary resistance are emerging problems. We have identified TJP1 as a determinant of plasma cell proteasome inhibitor susceptibility. TJP1 suppressed expression of the catalytically active immunoproteasome subunits LMP7 and LMP2, decreased proteasome activity, and enhanced proteasome inhibitor sensitivity in vitro and in vivo. This occurred through TJP1-mediated suppression of EGFR/JAK1/STAT3 signaling, which modulated LMP7 and LMP2 levels. In the clinic, high TJP1 expression in patient myeloma cells was associated with a significantly higher likelihood of responding to bortezomib and a longer response duration, supporting the use of TJP1 as a biomarker to identify patients most likely to benefit from proteasome inhibitors.
Indexed as
AnimalsAntineoplastic AgentsBiomarkers, TumorBlotting, WesternBortezomibCell Line, TumorCysteine EndopeptidasesDisease-Free SurvivalErbB ReceptorsErlotinib HydrochlorideGene Expression ProfilingGene Expression Regulation, NeoplasticHumansJanus Kinase 1Mice, SCIDMultiple MyelomaAntineoplastic AgentsBiomarkers, TumorBortezomibCysteine EndopeptidasesEGFR protein, humanErbB ReceptorsErlotinib HydrochlorideJAK1 protein, humanJanus Kinase 1LMP-2 proteinLMP7 proteinProteasome Endopeptidase ComplexProteasome InhibitorsSTAT3 Transcription FactorTJP1 protein, humanZonula Occludens-1 Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.